Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.06 HKD | +3.49% | +6.35% | -32.82% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- With an enterprise value anticipated at 4.86 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.82% | 3.55B | C+ | ||
-1.26% | 89.46B | A- | ||
+2.76% | 40.74B | A- | ||
-9.68% | 33.03B | B- | ||
+55.32% | 24.68B | A | ||
-16.47% | 15.12B | C | ||
-9.21% | 12.81B | B- | ||
-12.11% | 11.79B | D+ | ||
-43.61% | 11.64B | B | ||
+7.79% | 8.9B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 1877 Stock
- Ratings Shanghai Junshi Biosciences Co., Ltd.